XML 43 R28.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation (Tables)
 3 Months Ended
Mar. 31, 2022
Share-based Payment Arrangement [Abstract]  
Schedule of Stock-Based Compensation Expense
Stock-based compensation expense for options granted, restricted stock awards (“RSAs”), RSAs with non-market performance and service conditions (“PSAs”), restricted stock units (“RSUs”) and stock appreciation rights (“SARs”) is reflected in the condensed consolidated statements of operations and comprehensive loss as follows:
 THREE MONTHS ENDED 
MARCH 31,
(in thousands)20222021
Cost of goods sold$162 $507 
Selling, general and administrative3,134 6,255 
Research and development1,336 1,987 
Total$4,632 $8,749 
Schedule of Stock Options Activity
The following table summarizes the stock option activity under the Plans:
NUMBER OF
SHARES		WEIGHTED
 AVERAGE EXERCISE PRICE		WEIGHTED
AVERAGE
REMAINING
CONTRACTUAL
LIFE (YEARS)		AGGREGATE
INTRINSIC
VALUE
(000’s)
Options outstanding at December 31, 2021
6,550,610 $26.87 
Granted673,888 8.73 
Canceled(513,013)23.91 
Options outstanding at March 31, 2022
6,711,485 $25.27 6.4$2,354 
Options exercisable at March 31, 2022
4,569,275 $30.42 5.1$1,716 
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity
The following table summarizes the RSA, including PSA, activity under the Plans:
NUMBER OF
SHARES		WEIGHTED AVERAGE
FAIR VALUE PER SHARE
Non-vested RSAs at December 31, 2021
977,244 $18.32 
Granted347,814 8.80 
Vested(132,905)34.07 
Canceled(114,408)19.43 
Non-vested RSAs at March 31, 2022
1,077,745 13.21 
The following table summarizes the RSU activity under the Plans:
NUMBER OF
SHARES		WEIGHTED AVERAGE
FAIR VALUE PER SHARE
Non-vested RSUs at December 31, 2021
156,873 $14.88 
Granted1,989 6.88 
Vested(7,143)7.00 
Canceled(437)16.22 
Non-vested RSUs at March 31, 2022
151,282 15.14 
Schedule of Stock Appreciation Rights
The following table summarizes the SARs activity under the Plans:
NUMBER OF
SHARES		WEIGHTED 
AVERAGE
EXERCISE PRICE		WEIGHTED
AVERAGE
REMAINING
CONTRACTUAL
LIFE (YEARS)		AGGREGATE
INTRINSIC
VALUE
(000’s)
SARs outstanding at December 31, 2021
238,349 $27.67 
Granted3,000 6.97 
Canceled(13,434)28.02 
SARs outstanding at March 31, 2022
227,915 $27.37 2.8$7 
SARs exercisable at March 31, 2022
96,106 $39.26 1.9$—